SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non–Small-Cell Lung Cancer—A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group
5 references·0 citing·22 second hop
Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non–Small-Cell Lung Cancer—A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group (2007)Economic Analysis of NCIC CTG JBR.10: A R…Methods for the Economic Evaluation of Health Care Programmes (2005)Methods for the Economic Eval…When does quality‐adjusting life‐years matter in cost‐effectiveness analysis? (2004)When does quality‐adjusting l…Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer (2002)Economic Analysis of Vinorelb…Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-Small-Cell Lung Cancer (2002)Economic Analysis of the TAX …How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)How attractive does a new tec…Alternative to Mental Hospital Treatment (1980)A methodological framework for assessing health indices (1985)Measurement of health state utilities for economic appraisal (1986)The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument (1993)A study of the quality of life and cost-utility of renal transplantation (1996)A within-trial cost-effectiveness analysis of primary care referral to a commercial provider for weight loss treatment, relative to standard care—an international randomised controlled trial (2012)Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. (1990)Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. (1995)Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC) (2008)The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer (2022)Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness (1995)Cost-Effectiveness in Health and Medicine (1996)Willingness to Pay for a Quality-adjusted Life Year (2000)Measuring Preferences for Cost-Utility Analysis (2007)QALYs vs DALYs vs LYs gained: What are the differences, and what difference do they make for health care priority setting? (2009)Value-based medicine: concepts and application (2015)Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues (1991)The Journal's Policy on Cost-Effectiveness Analyses (1994)The Burden of Illness of Cancer: Economic Cost and Quality of Life (2001)The estimation of a preference-based measure of health from the SF-36 (2002)Systematic reviews: CRD's guidance for undertaking reviews in health care (2010)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)
this work references cited by second hop

References

  • 2005Methods for the Economic Evaluation of Health Care Programmes13,647 cited
  • 1992How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.1,581 cited
  • 2004When does quality‐adjusting life‐years matter in cost‐effectiveness analysis?114 cited
  • 2002Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer74 cited
  • 2002Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-Small-Cell Lung Cancer71 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work